Patent
US 10,894,020HYBRID NANOPARTICLES CONTAINING BORON-DOPED GRAPHENE QUANTUM DOTS AND APPLICATIONS THEREOF
Shang-Hsiu Hu
US
Copyright © 2026 Matter42. All rights reserved.
Patent
Atlas literature
Patent
US 10,894,020Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 shows the self-assembly process and structure of a hybrid nanoparticle according to one embodiment of the present invention, in which an aggregate is …
FIG. 2B shows a TEM image of polyamidoamine dendrimers modified with phenylboronic acid (an example of the pH-responsive dendrimer). According to
FIG. 3B shows a TEM image of B-GQD/pH- Den hybrid nanoparticles at pH 6.6, in which the scale bar represents 500 nm; [0
FIG. 4A shows a TEM image of B-GQD/pH-Den hybrid nanoparticles subjected to a high frequency magnetic field (HFMF) for 15 minutes, in which the scale bar …
FIG. 5A shows fluorescence signal distribution of the fluorescently labeled B-GQD/pH-Den hybrid nanoparticles in a solid collagen hy d rogel bef SVG …
FIG. 6A, at various tumor depths, the aforementioned hybrid nanoparticles were mainly distributed at the periphery of the tumor spheroid before being subjected …
FIG. 7 shows the distribution of B-GQD/pH-Den hybrid nanoparticles with or without the rabies virus glycoprotein fragment (RVG) in the brain and heart of mice; …
FIG. 8, the RVG modification increased the accumulation of the hybrid nanoparticles in the spinal cord, suggesting that the hybrid nanoparticles may accomplish …
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A hybrid nanoparticle, comprising: an aggregate assembled from a plurality of polymeric molecules, and a plurality of boron-doped graphene quantum dots localized in the aggregate, wherein the polymeric molecule further binds to a hydrophilic drug or a first hydrophobic drug; wherein the boron-doped graphene quantum dot further binds to a second hydrophobic drug; wherein the hybrid nanoparticle is disassembled by applying a high-frequency magnetic field of 50 to 600 k Hz; wherein the hybrid nanoparticle has a particle size of 160-450 nm; wherein each of the plurality of boron-doped graphene quantum dots has a particle size of 2-5 nm. Currently amended
The hybrid nanoparticle of claim 1, wherein the polymeric molecule is a stimuli-responsive polymeric molecule. Original
The hybrid nanoparticle of claim 1, further comprising a targeting molecule. Original
A method of controlling disassembly of a hybrid nanoparticle, comprising the steps of (a) obtaining the hybrid nanoparticle of claim 1, and (b) applying a high-frequency magnetic field of 50 to 600 k H z to the hybrid nanoparticle to induce disassembly thereof. Withdrawn
A method of preparing a tumor-penetrating drug carrier, comprising the step of incorporating a plurality of boron-doped graphene quantum dots in an aggregate assembled from a plurality of polymeric molecules to obtain a hybrid nanoparticle of claim 1. Withdrawn
4, Canceled
Canceled
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
hybrid nanoparticle
Materials described outside the worked examples.
polymeric molecule (stimuli-responsive/pH-responsive dendrimer)
boron-doped graphene quantum dot
Measurements and analyses referenced in the patent, with their drawing references.
FIG. 2B shows a TEM image of polyamidoamine dendrimers modified with phenylboronic acid (an example of the pH-responsive dendrimer). According to
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
hybrid nanoparticle particle size | 160–450 | polymeric molecule (stimuli-responsive/pH-responsive dendrimer) |
boron-doped graphene quantum dot particle size |
Patent
Atlas literature
Patent
US 10,894,020Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 shows the self-assembly process and structure of a hybrid nanoparticle according to one embodiment of the present invention, in which an aggregate is …
FIG. 2B shows a TEM image of polyamidoamine dendrimers modified with phenylboronic acid (an example of the pH-responsive dendrimer). According to
FIG. 3B shows a TEM image of B-GQD/pH- Den hybrid nanoparticles at pH 6.6, in which the scale bar represents 500 nm; [0
FIG. 4A shows a TEM image of B-GQD/pH-Den hybrid nanoparticles subjected to a high frequency magnetic field (HFMF) for 15 minutes, in which the scale bar …
FIG. 5A shows fluorescence signal distribution of the fluorescently labeled B-GQD/pH-Den hybrid nanoparticles in a solid collagen hy d rogel bef SVG …
FIG. 6A, at various tumor depths, the aforementioned hybrid nanoparticles were mainly distributed at the periphery of the tumor spheroid before being subjected …
FIG. 7 shows the distribution of B-GQD/pH-Den hybrid nanoparticles with or without the rabies virus glycoprotein fragment (RVG) in the brain and heart of mice; …
FIG. 8, the RVG modification increased the accumulation of the hybrid nanoparticles in the spinal cord, suggesting that the hybrid nanoparticles may accomplish …
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A hybrid nanoparticle, comprising: an aggregate assembled from a plurality of polymeric molecules, and a plurality of boron-doped graphene quantum dots localized in the aggregate, wherein the polymeric molecule further binds to a hydrophilic drug or a first hydrophobic drug; wherein the boron-doped graphene quantum dot further binds to a second hydrophobic drug; wherein the hybrid nanoparticle is disassembled by applying a high-frequency magnetic field of 50 to 600 k Hz; wherein the hybrid nanoparticle has a particle size of 160-450 nm; wherein each of the plurality of boron-doped graphene quantum dots has a particle size of 2-5 nm. Currently amended
The hybrid nanoparticle of claim 1, wherein the polymeric molecule is a stimuli-responsive polymeric molecule. Original
The hybrid nanoparticle of claim 1, further comprising a targeting molecule. Original
A method of controlling disassembly of a hybrid nanoparticle, comprising the steps of (a) obtaining the hybrid nanoparticle of claim 1, and (b) applying a high-frequency magnetic field of 50 to 600 k H z to the hybrid nanoparticle to induce disassembly thereof. Withdrawn
A method of preparing a tumor-penetrating drug carrier, comprising the step of incorporating a plurality of boron-doped graphene quantum dots in an aggregate assembled from a plurality of polymeric molecules to obtain a hybrid nanoparticle of claim 1. Withdrawn
4, Canceled
Canceled
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
hybrid nanoparticle
Materials described outside the worked examples.
polymeric molecule (stimuli-responsive/pH-responsive dendrimer)
boron-doped graphene quantum dot
Measurements and analyses referenced in the patent, with their drawing references.
FIG. 2B shows a TEM image of polyamidoamine dendrimers modified with phenylboronic acid (an example of the pH-responsive dendrimer). According to
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
hybrid nanoparticle particle size | 160–450 | polymeric molecule (stimuli-responsive/pH-responsive dendrimer) |
boron-doped graphene quantum dot particle size |
Patent
Atlas literature
Patent
US 10,894,020Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 shows the self-assembly process and structure of a hybrid nanoparticle according to one embodiment of the present invention, in which an aggregate is …
FIG. 2B shows a TEM image of polyamidoamine dendrimers modified with phenylboronic acid (an example of the pH-responsive dendrimer). According to
FIG. 3B shows a TEM image of B-GQD/pH- Den hybrid nanoparticles at pH 6.6, in which the scale bar represents 500 nm; [0
FIG. 4A shows a TEM image of B-GQD/pH-Den hybrid nanoparticles subjected to a high frequency magnetic field (HFMF) for 15 minutes, in which the scale bar …
FIG. 5A shows fluorescence signal distribution of the fluorescently labeled B-GQD/pH-Den hybrid nanoparticles in a solid collagen hy d rogel bef SVG …
FIG. 6A, at various tumor depths, the aforementioned hybrid nanoparticles were mainly distributed at the periphery of the tumor spheroid before being subjected …
FIG. 7 shows the distribution of B-GQD/pH-Den hybrid nanoparticles with or without the rabies virus glycoprotein fragment (RVG) in the brain and heart of mice; …
FIG. 8, the RVG modification increased the accumulation of the hybrid nanoparticles in the spinal cord, suggesting that the hybrid nanoparticles may accomplish …
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A hybrid nanoparticle, comprising: an aggregate assembled from a plurality of polymeric molecules, and a plurality of boron-doped graphene quantum dots localized in the aggregate, wherein the polymeric molecule further binds to a hydrophilic drug or a first hydrophobic drug; wherein the boron-doped graphene quantum dot further binds to a second hydrophobic drug; wherein the hybrid nanoparticle is disassembled by applying a high-frequency magnetic field of 50 to 600 k Hz; wherein the hybrid nanoparticle has a particle size of 160-450 nm; wherein each of the plurality of boron-doped graphene quantum dots has a particle size of 2-5 nm. Currently amended
The hybrid nanoparticle of claim 1, wherein the polymeric molecule is a stimuli-responsive polymeric molecule. Original
The hybrid nanoparticle of claim 1, further comprising a targeting molecule. Original
A method of controlling disassembly of a hybrid nanoparticle, comprising the steps of (a) obtaining the hybrid nanoparticle of claim 1, and (b) applying a high-frequency magnetic field of 50 to 600 k H z to the hybrid nanoparticle to induce disassembly thereof. Withdrawn
A method of preparing a tumor-penetrating drug carrier, comprising the step of incorporating a plurality of boron-doped graphene quantum dots in an aggregate assembled from a plurality of polymeric molecules to obtain a hybrid nanoparticle of claim 1. Withdrawn
4, Canceled
Canceled
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
hybrid nanoparticle
Materials described outside the worked examples.
polymeric molecule (stimuli-responsive/pH-responsive dendrimer)
boron-doped graphene quantum dot
Measurements and analyses referenced in the patent, with their drawing references.
FIG. 2B shows a TEM image of polyamidoamine dendrimers modified with phenylboronic acid (an example of the pH-responsive dendrimer). According to
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
hybrid nanoparticle particle size | 160–450 | polymeric molecule (stimuli-responsive/pH-responsive dendrimer) |
boron-doped graphene quantum dot particle size |
Patent
Atlas literature
Patent
US 10,894,020Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 shows the self-assembly process and structure of a hybrid nanoparticle according to one embodiment of the present invention, in which an aggregate is …
FIG. 2B shows a TEM image of polyamidoamine dendrimers modified with phenylboronic acid (an example of the pH-responsive dendrimer). According to
FIG. 3B shows a TEM image of B-GQD/pH- Den hybrid nanoparticles at pH 6.6, in which the scale bar represents 500 nm; [0
FIG. 4A shows a TEM image of B-GQD/pH-Den hybrid nanoparticles subjected to a high frequency magnetic field (HFMF) for 15 minutes, in which the scale bar …
FIG. 5A shows fluorescence signal distribution of the fluorescently labeled B-GQD/pH-Den hybrid nanoparticles in a solid collagen hy d rogel bef SVG …
FIG. 6A, at various tumor depths, the aforementioned hybrid nanoparticles were mainly distributed at the periphery of the tumor spheroid before being subjected …
FIG. 7 shows the distribution of B-GQD/pH-Den hybrid nanoparticles with or without the rabies virus glycoprotein fragment (RVG) in the brain and heart of mice; …
FIG. 8, the RVG modification increased the accumulation of the hybrid nanoparticles in the spinal cord, suggesting that the hybrid nanoparticles may accomplish …
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A hybrid nanoparticle, comprising: an aggregate assembled from a plurality of polymeric molecules, and a plurality of boron-doped graphene quantum dots localized in the aggregate, wherein the polymeric molecule further binds to a hydrophilic drug or a first hydrophobic drug; wherein the boron-doped graphene quantum dot further binds to a second hydrophobic drug; wherein the hybrid nanoparticle is disassembled by applying a high-frequency magnetic field of 50 to 600 k Hz; wherein the hybrid nanoparticle has a particle size of 160-450 nm; wherein each of the plurality of boron-doped graphene quantum dots has a particle size of 2-5 nm. Currently amended
The hybrid nanoparticle of claim 1, wherein the polymeric molecule is a stimuli-responsive polymeric molecule. Original
The hybrid nanoparticle of claim 1, further comprising a targeting molecule. Original
A method of controlling disassembly of a hybrid nanoparticle, comprising the steps of (a) obtaining the hybrid nanoparticle of claim 1, and (b) applying a high-frequency magnetic field of 50 to 600 k H z to the hybrid nanoparticle to induce disassembly thereof. Withdrawn
A method of preparing a tumor-penetrating drug carrier, comprising the step of incorporating a plurality of boron-doped graphene quantum dots in an aggregate assembled from a plurality of polymeric molecules to obtain a hybrid nanoparticle of claim 1. Withdrawn
4, Canceled
Canceled
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
hybrid nanoparticle
Materials described outside the worked examples.
polymeric molecule (stimuli-responsive/pH-responsive dendrimer)
boron-doped graphene quantum dot
Measurements and analyses referenced in the patent, with their drawing references.
FIG. 2B shows a TEM image of polyamidoamine dendrimers modified with phenylboronic acid (an example of the pH-responsive dendrimer). According to
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
hybrid nanoparticle particle size | 160–450 | polymeric molecule (stimuli-responsive/pH-responsive dendrimer) |
boron-doped graphene quantum dot particle size |
pH-responsive dendrimer
targeting molecule
rabies virus glycoprotein (RVG) or peptide fragment thereof
palbociclib
hydrophilic drug
hydrophobic drug
FIG. 3B shows a TEM image of B-GQD/pH- Den hybrid nanoparticles at pH 6.6, in which the scale bar represents 500 nm; [0
FIG. 4A shows a TEM image of B-GQD/pH-Den hybrid nanoparticles subjected to a high frequency magnetic field (HFMF) for 15 minutes, in which the scale bar …
boron-doped graphene quantum dot |
pH-responsive dendrimer molecular weight | 1000–60000 | pH-responsive dendrimer |
high-frequency magnetic field for nanoparticle disassembly | 50–600 | — |
Temperature | 150–400 °C | — |
Duration | 2–48 hours | — |
Duration | 10–30 minutes | — |
Thickness | 2–5 nm | — |
Thickness | 50–80 nm | — |
Thickness | 160–250 nm | — |
Temperature | 50–600 k | — |
Thickness | 160–450 nm | — |
pH-responsive dendrimer
targeting molecule
rabies virus glycoprotein (RVG) or peptide fragment thereof
palbociclib
hydrophilic drug
hydrophobic drug
FIG. 3B shows a TEM image of B-GQD/pH- Den hybrid nanoparticles at pH 6.6, in which the scale bar represents 500 nm; [0
FIG. 4A shows a TEM image of B-GQD/pH-Den hybrid nanoparticles subjected to a high frequency magnetic field (HFMF) for 15 minutes, in which the scale bar …
boron-doped graphene quantum dot |
pH-responsive dendrimer molecular weight | 1000–60000 | pH-responsive dendrimer |
high-frequency magnetic field for nanoparticle disassembly | 50–600 | — |
Temperature | 150–400 °C | — |
Duration | 2–48 hours | — |
Duration | 10–30 minutes | — |
Thickness | 2–5 nm | — |
Thickness | 50–80 nm | — |
Thickness | 160–250 nm | — |
Temperature | 50–600 k | — |
Thickness | 160–450 nm | — |
pH-responsive dendrimer
targeting molecule
rabies virus glycoprotein (RVG) or peptide fragment thereof
palbociclib
hydrophilic drug
hydrophobic drug
FIG. 3B shows a TEM image of B-GQD/pH- Den hybrid nanoparticles at pH 6.6, in which the scale bar represents 500 nm; [0
FIG. 4A shows a TEM image of B-GQD/pH-Den hybrid nanoparticles subjected to a high frequency magnetic field (HFMF) for 15 minutes, in which the scale bar …
boron-doped graphene quantum dot |
pH-responsive dendrimer molecular weight | 1000–60000 | pH-responsive dendrimer |
high-frequency magnetic field for nanoparticle disassembly | 50–600 | — |
Temperature | 150–400 °C | — |
Duration | 2–48 hours | — |
Duration | 10–30 minutes | — |
Thickness | 2–5 nm | — |
Thickness | 50–80 nm | — |
Thickness | 160–250 nm | — |
Temperature | 50–600 k | — |
Thickness | 160–450 nm | — |
pH-responsive dendrimer
targeting molecule
rabies virus glycoprotein (RVG) or peptide fragment thereof
palbociclib
hydrophilic drug
hydrophobic drug
FIG. 3B shows a TEM image of B-GQD/pH- Den hybrid nanoparticles at pH 6.6, in which the scale bar represents 500 nm; [0
FIG. 4A shows a TEM image of B-GQD/pH-Den hybrid nanoparticles subjected to a high frequency magnetic field (HFMF) for 15 minutes, in which the scale bar …
boron-doped graphene quantum dot |
pH-responsive dendrimer molecular weight | 1000–60000 | pH-responsive dendrimer |
high-frequency magnetic field for nanoparticle disassembly | 50–600 | — |
Temperature | 150–400 °C | — |
Duration | 2–48 hours | — |
Duration | 10–30 minutes | — |
Thickness | 2–5 nm | — |
Thickness | 50–80 nm | — |
Thickness | 160–250 nm | — |
Temperature | 50–600 k | — |
Thickness | 160–450 nm | — |